Popping up today,
shaping tomorrow.

Empowering Visionaries in HealthcarE

Innovators Pop-Up was born out of the idea that early innovators need a space dedicated to showcasing their technology that allows for connection with key industry influencers, provides a compelling and memorable experience for attendees, and delivers enduring impact.

Empowering Visionaries in HealthcarE

Innovators Pop-Up was born out of the idea that early innovators need a space dedicated to showcasing their technology that allows for connection with key industry influencers, provides a compelling and memorable experience for attendees, and delivers enduring impact.

Stay tuned for the next pop-up

Orlando, Fl
During AAO 2025

Time & Date TBD

INNOVATION AND ADVENTURE PROMISED

Be the first to know and subscribe to our newsletter!

Join the Newsletter

JOIN US IN THE INNOVATION PLAYGROUND

This dynamic and immersive event will showcase cutting-edge healthcare innovations in an interactive “playground.” Dive into a world where groundbreaking ophthalmology meets hands-on exploration, fostering connections and sparking revolutionary ideas.

Get HANDS-ON with the
latest technologies in
ophthalmology

Connect with industry
leaders and fellow
visionaries

Champion innovators as
they take the “hot seat”
where they’ll be
interviewed by key
industry leaders

Learn More »

Be part of shaping the
next wave of ophthalmic
advancements

ready to showcase
your healthcare technology?

INNOVATOR

SHOWCASED INNOVATORS

Sponsors

Want to support the innovator ecosystem?

Sponsor

Powered By:

iDoc Social Logo

Stay in the Pop-Up Loop!

Pop into our exclusive email list and be the first to know where Innovators Pop-Up will pop up next. It’s like a surprise party for your inbox – but way cooler.

© 2024 Innovators Pop-up. All rights reserved.
Linkedin-in

Amaros

BIO

Amaros offers an AI-powered platform that accelerates ophthalmology clinical trials and opens up new market opportunities for therapeutic companies.

Its Ophthalmic Answer Engine™ identifies eligible patients more efficiently, reduces costs, and enhances the overall patient experience—bringing innovation to the forefront of eye care.

Atia Vision

BIO

Atia Vision, a Shifamed portfolio company, is developing a next-generation technology for cataract surgery with its OmniVu™ Lens System, a dual-optic presbyopia-correcting intraocular lens technology. This system is designed to:  

– Deliver refractive predictability – Provide continuous vision across a broad range of defocus

– Preserve natural image quality while minimizing visual disturbances – Stabilize intraocular structures and promote capsular bag health

– Preserve future options for surgeons and patients through its modular, adaptable platform  

The OmniVu™ Lens System combines a fixed power front optic made from hydrophobic acrylic with a fluid-filled, shape-changing base made from silicone. This design is based on learnings from prior generation technologies and aims to address gaps in current solutions, with the goal of providing improved visual outcomes while maintaining long-term stability and flexibility.

Myra Vision

BIO

Seeking to answer the need for personalized glaucoma care, Myra Vision is developing the Calibreye™ Titratable Glaucoma TherapyTM (TGT) Surgical System—the next-generation solution designed for patients with glaucoma who require low intraocular pressure (IOP).

The Calibreye TGT Surgical System aims to:

  • Personalize glaucoma care by enabling adjustable outflow control
  • Provide a safe solution to IOP reduction by using biocompatible materials that conform to the eye
  • Enhance the confidence of ophthalmologists during implantation, by leveraging the well-established method of ab externo delivery
  • Reverse hypotony due to excessive flow with an adjustable feature built into its innovative design


As an unprecedented development in glaucoma care, the Calibreye TGT System is designed to improve outcomes and minimize complications associated with conventional approaches.

The Calibreye TGT Surgical System is for investigational use only and is not for sale in the US or outside the US.

NuLids

BIO

NuLiDS is an innovative eyelid care technology developed by John Olkowski, MD, a board-certified ophthalmologist and corneal specialist. Dr. Olkowski recognized the central role of eyelid care in ocular health and developed the safe, effective, and convenient NuLIDS to proactively manage common, under-diagnosed conditions like dry eye. The San Diego-based company has sold 25,000 “At Home” units and recently introduced the “PRO” in-practice version of NuLIDS globally.

NuLIDS is a small handheld electromechanical device which operates by low-speed oscillation utilizing single use disposable silicon tips. The comfortable 1-2 minute vibrating treatment is performed on a closed eye to (1) clean the eyelids and eyelashes, (2) massage the eyelids to enhance meibomian gland production and (3) remove demodex mites. With increased recognition of proactive ocular wellness, NuLIDS is uniquely positioned to enable convenient and affordable high quality lid hygiene in the office and at home.

Oculotix

BIO

Oculotix is applying AI-based software to optimize intraocular lens (IOL) model selection to improve patient vision outcomes and boost surgical efficiency in cataract and lens exchange procedures. The software provides surgeons with predictive analytics of vision outcomes and a recommended IOL model to achieve the best possible outcome for their patients.

Vision outcomes are predicted and compared to the patient’s expectations for day/night driving, spectacle-independence, and potential visual artifacts. This information provides the surgeon and patient with a quantitative pre-operative assessment, increasing the likelihood of patient satisfaction with surgical outcomes while also saving clinical time and resources. The software is particularly useful in boosting confidence in adoption of advanced technology IOLs, which can have benefits for patients well suited to the technologies available.

Osheru

BIO

Osheru is a bold and creative medical device company specializing in innovative solutions for skin surgery. Founded by Drs. Patricia and Knute Buehler, Osheru aims to create and lead a new paradigm for eyelid surgery through its revolutionary Ziplyft device, designed to enhance surgical precision and patient recovery. The company’s breakthrough approach addresses key challenges in eyelid surgery, promising improved outcomes and reduced downtime for patients with enhanced efficiency and accuracy for surgeons. Osheru is focused on minimally invasive alternatives to traditional skin removal procedures and is poised to transform not only the field of ophthalmology but also dermatology, and plastic surgery. 

Bausch + Lomb

BIO

Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,000 employees and a presence in nearly 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit www.bausch.com and connect with us on X, LinkedIn, Facebook and Instagram.

BTIG

BIO

Leveraging BTIG’s full resources, our Healthcare Investment Banking Group works alongside established and emerging, private and public healthcare companies to help them grow and capitalize on valuable market opportunities. With seasoned healthcare-focused banking professionals in Boston, New York and San Francisco, we collaborate with clients to execute transformative transactions.

We deliver deep sector and transactional expertise across biotechnology, life science and diagnostic tools, medical technology and specialty pharmaceuticals. Regardless of the stage of their development, BTIG’s knowledgeable, senior team delivers operational and financial guidance to corporate clients across the healthcare spectrum. And, with our extensive industry relationships, we offer investor perspective and insights that help adjust and evolve corporate strategy.

LELU Management

BIO

Lelu Management is a dedicated service provider specializing in healthcare solutions. Our focus is on empowering healthcare organizations with innovative strategies that streamline operations, enhance financial management, and optimize overall efficiency. We partner with industry leaders to offer tailored solutions that meet the unique needs of the healthcare sector, ensuring our clients can focus on delivering high-quality patient care while we handle the rest.

Market Scope

BIO

Market Scope is the leading source for market intelligence in ophthalmology. We’ve been focusing on the global ophthalmic market since 1996, performing syndicated and primary market research and embedding ourselves in the field. Whether you are looking to launch a product, considering a merger or acquisition, investing, working on research and product development, or strategic planning, we can get the data you need. Because better data means better decisions.

True North

BIO

True North Contract Research is a dynamic and rapidly growing Contract Research Organization (CRO) specializing in Ophthalmology research. We strive to deliver an experience that is second to none to our sponsor partners and site partners. Our longstanding commitment to advancing the field of ophthalmology through clinical research has provided us with the experience to execute trials efficiently with a focus on accuracy and compliance. We merge FDA and clinical site perspectives to identify effective solutions that are agreeable to both parties and then mitigate roadblocks to achieve trial endpoints. One of our greatest strengths is uniting with sponsoring companies as a seamless team that makes well-thought-through decisions on time.